Trials / Completed
CompletedNCT06725238
Acute-to-chronic Glycemic Ratio (ACGR) is a Marker of DFUs .
The Interplay of Acute-to-Chronic Glycemic Ratio With Other Biomarkers in Diabetic Foot Ulcers: An Effect is Not Related to the Therapeutic Remedies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- University of Diyala · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Diabetic foot ulcers (DFUs) have resulted from peripheral arterial ischemia and peripheral neuropathy that are complicated with infections and amputation of the lower extremities. Uncontrolled glycemic status and significantly higher glycosylated hemoglobin (HbA1c) are associated with DFUs. This study aimed to assess the acute-to-chronic glycemic ratio (ACGR) in type 2 diabetes (T2D) with DFUs and compare it with those without DFUs, considering the relationships of this ratio with other indices that characterized the pathogenesis of T2D. This cross-sectional study was conducted on T2D with DFUs and non-DFUs. The primary outcome is ACGR. The secondary outcomes are indices related to the anthropometric, metabolic, and hematological variables.
Detailed description
DFUs are a macrovascular complication of diabetes mellitus resulting from peripheral artery disease and peripheral neuropathy that commonly affects the lower extremities. The DFUs are usually classified and scored according to the clinical findings. The ACGR is computed by dividing the acute (or current, or on admission in hospital) plasma glucose level by the chronic plasma glucose level calculated using the current (or on admission) HbA1c value.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Acute-to-chronic glycemic ratio | This ratio could be related to diabetic foot ulcer |
Timeline
- Start date
- 2024-05-01
- Primary completion
- 2024-11-01
- Completion
- 2024-11-10
- First posted
- 2024-12-10
- Last updated
- 2024-12-10
Locations
1 site across 1 country: Iraq
Source: ClinicalTrials.gov record NCT06725238. Inclusion in this directory is not an endorsement.